The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.

The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.

Item
http://www.wikidata.org/entity/Q34463641
Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis)Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Central Nervous System Complications in Children Receiving Chemotherapy or Hematopoietic Stem Cell TransplantationAsparaginase-associated toxicity in children with acute lymphoblastic leukemia.Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study.Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia.Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T and B cell acute lymphoblastic leukemias in vivo.Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation.
P2860

The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.

Item
http://www.wikidata.org/entity/Q34463641
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The toxicity of very prolonged ...... special focus on dyslipidemia.
@ast
The toxicity of very prolonged ...... special focus on dyslipidemia.
@en
The toxicity of very prolonged ...... special focus on dyslipidemia.
@nl
type
label
The toxicity of very prolonged ...... special focus on dyslipidemia.
@ast
The toxicity of very prolonged ...... special focus on dyslipidemia.
@en
The toxicity of very prolonged ...... special focus on dyslipidemia.
@nl
prefLabel
The toxicity of very prolonged ...... special focus on dyslipidemia.
@ast
The toxicity of very prolonged ...... special focus on dyslipidemia.
@en
The toxicity of very prolonged ...... special focus on dyslipidemia.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
The toxicity of very prolonged ...... special focus on dyslipidemia.
@en
P2093
P2860
P304
P31
P356
10.3324/HAEMATOL.2014.109413
P433
P478
P50
P577
P5875
P698
P921
P932